Bisphosphonate dose and incidence of fractures in postmenopausal osteoporosis

Bone

Volumn 44, Issue 5, 2009, Pages 766-771

  Makras, P ^a   Hamdy, N A T ^a   Zwinderman, A H ^b   Ballieux, B E P B ^a   Papapoulos, S E ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Bisphosphonates; Diaphyseal femoral fracture; Fractures; Pamidronate; Postmenopausal osteoporosis

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; ETIDRONIC ACID; PAMIDRONIC ACID; VITAMIN D;

AGED; ARTICLE; BONE DENSITY; BONE FRAGILITY; BONE STRENGTH; CHRONIC DRUG ADMINISTRATION; DISEASE SEVERITY; DRUG DOSE REGIMEN; FEMALE; FEMUR SUBTROCHANTERIC FRACTURE; FRAGILITY FRACTURE; HUMAN; MAJOR CLINICAL STUDY; POSTMENOPAUSE OSTEOPOROSIS; RETROSPECTIVE STUDY; RISK REDUCTION; VERTEBRA FRACTURE;

AGED; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; DRUG ADMINISTRATION SCHEDULE; FEMALE; FRACTURES, BONE; HUMANS; OSTEOPOROSIS, POSTMENOPAUSAL; RETROSPECTIVE STUDIES;

EID: 63449097437     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2009.01.371     Document Type: Article

References (28)

1. Papapoulos S.E. Bisphosphonates for postmenopausal osteoporosis. In: Rosen C.J. (Ed). Primer on the metabolic bone diseases and disorders of mineral metabolism (2008), American Society for Bone and Mineral Research, Washington DC 237-241
2. Drake M.T., Clarke B.L., and Khosla S. Bisphosphonates: mechanisms of action and role in clinical practice. Mayo. Clin. Proc. 83 (2008) 1032-1045
3. Papapoulos S.E. Bisphosphonates: how do they work?. Best. Pract. Res. Clin. Endocrinol. Metab. 22 (2008) 831-847
4. Cremers S.C., Pillai G., and Papapoulos S.E. Pharmacokinetics/pharmacodynamics of bisphosphonates: use for optimisation of intermittent therapy for osteoporosis. Clin. Pharmacokinet. 44 (2005) 551-570
5. Ott S.M. Long-term safety of bisphosphonates. J. Clin. Endocrinol. Metab. 90 (2005) 1897-1899
6. Mellstrom D.D., Sorensen O.H., Goemaere S., et al. Seven years of treatment with risedronate in women with postmenopausal osteoporosis. Calcif. Tissue. Int. 75 (2004) 462-468
7. Bone H.G., Hosking D., Devogelaer J.P., et al. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N. Engl. J. Med. 350 (2004) 1189-1199
8. Black D.M., Schwartz A.V., Ensrud K.E., et al. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 296 (2006) 2927-2938
9. Odvina C.V., Zerwekh J.E., Rao D.S., et al. Severely suppressed bone turnover: a potential complication of alendronate therapy. J. Clin. Endocrinol. Metab. 90 (2005) 1294-1301
10. Goh S.K., Yang K.Y., Koh J.S., et al. Subtrochanteric insufficiency fractures in patients on alendronate therapy: a caution. J. Bone. Joint. Surg. Br. 89 (2007) 349-353
11. Kwek E.B., Goh S.K., Koh J.S., et al. An emerging pattern of subtrochanteric stress fractures: a long-term complication of alendronate therapy?. Injury 39 (2008) 224-231
12. Visekruna M., Wilson D., and McKiernan F.E. Severely suppressed bone turnover and atypical skeletal fragility. J. Clin. Endocrinol. Metab. 93 (2008) 2948-2952
13. Lenart B.A., Lorich D.G., and Lane J.M. Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate. N. Engl. J. Med. 358 (2008) 1304-1306
14. Cremers S., Sparidans R., den H.J., et al. A pharmacokinetic and pharmacodynamic model for intravenous bisphosphonate (pamidronate) in osteoporosis. Eur. J. Clin. Pharmacol. 57 (2002) 883-890
15. Genant H.K., Jergas M., Palermo L., et al. Comparison of semiquantitative visual and quantitative morphometric assessment of prevalent and incident vertebral fractures in osteoporosis The Study of Osteoporotic Fractures Research Group. J. Bone. Miner. Res. 11 (1996) 984-996
16. Wu C.Y., Li J., Jergas M., and Jergas M. Genant HKl. Comparison of semiquantitative and quantitative techniques for the assessment of prevalent and incident vertebral fractures. Osteoporos. Int. 5 (1995) 354-370
17. Black D.M., Delmas P.D., Eastell R., et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N. Engl. J. Med. 356 (2007) 1809-1822
18. Lyles K.W., Colon-Emeric C.S., Magaziner J.S., et al. Zoledronic acid in reducing clinical fracture and mortality after hip fracture. N. Engl. J. Med. 357 (2007) 1799-1809
19. Chesnut III C.H., Skaag A., Christiansen C., et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J. Bone. Miner. Res. 19 (2004) 1241-1249
20. Cranney A., Wells G., Yetisir L., et al. Ibandronate for the prevention of non-vertebral fractures: a pooled analysis of individual patient data. Osteoporos. Int. (2008) 10.1007/s001 98-008-0653-8.
21. Brumsen C., Papapoulos S.E., Lips P., et al. Daily oral pamidronate in women and men with osteoporosis: a 3-year randomized placebo-controlled clinical trial with a 2-year open extension. J. Bone. Miner. Res. 17 (2002) 1057-1064
22. Papapoulos S.E., and Cremers S.C. Prolonged bisphosphonate release after treatment in children. N. Engl. J. Med. 356 (2007) 1075-1076
23. Harris S.T., Watts N.B., Genant H.K., et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. JAMA 282 (1999) 1344-1352
24. Recker R., Stakkestad J.A., Chesnut III C.H., et al. Insufficiently dosed intravenous ibandronate injections are associated with suboptimal antifracture efficacy in postmenopausal osteoporosis. Bone 34 (2004) 890-899
25. Reginster J., Minne H.W., Sorensen O.H., et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos. Int. 11 (2000) 83-91
26. Cummings S.R., Black D.M., Thompson D.E., et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 280 (1998) 2077-2082
27. Cranney A., Wells G., Willan A., et al. Meta-analyses of therapies for postmenopausal osteoporosis. II. Meta-analysis of alendronate for the treatment of postmenopausal women. Endocr. Rev. 23 (2002) 508-516
28. Delmas P.D., Genant H.K., Crans G.G., et al. Severity of prevalent vertebral fractures and the risk of subsequent vertebral and nonvertebral fractures: results from the MORE trial. Bone 33 (2003) 522-532